The “hay fever vaccine” is a colloquial UK term covering two very different treatments. Modern allergen immunotherapy via Grazax, Acarizax or Itulazax sublingual tablets is NICE-recommended and NHS-funded. Kenalog steroid injections have been withdrawn from NHS hay fever care and the MHRA has restricted private advertising.

Hay Fever Vaccine UK 2026: A Calm GP Guide to Allergen Immunotherapy on the NHS, Sublingual Tablets and Why Kenalog Is No Longer Recommended

Hay fever season in the UK can be miserable. Itchy eyes, constant sneezing, a blocked nose and fatigue can make work, sleep and exam revision genuinely difficult. Many sufferers reach a point where antihistamines and nasal sprays feel like they are not enough. That is often when people start searching for a “hay fever vaccine” – hoping for something stronger, something lasting, perhaps a single injection that sorts it out for the season.

The phrase is used loosely in 2026. For some people it means the old Kenalog steroid injection, still offered by some private clinics and advertised on social media as “the hay fever jab.” For others it means the modern allergen immunotherapy tablets now recommended by NICE and available on the NHS through specialist allergy clinics. These two treatments are clinically very different. One is a long-acting systemic steroid. The other is a disease-modifying treatment that retrains the immune system over three years.

This article explains what is actually available in the UK in 2026, what the NHS offers, why Kenalog has been withdrawn from NHS hay fever treatment, and how to access proper immunotherapy if your symptoms are not controlled by standard treatments.

What people actually mean by “hay fever vaccine” in 2026

The phrase “hay fever vaccine” is a colloquial term that has come to cover two clinically very different treatments in the UK. The first and modern meaning is allergen immunotherapy. This is a graded, repeated exposure to a small amount of the relevant allergen – grass pollen, tree pollen or house dust mite – with the aim of teaching the immune system to tolerate it rather than overreact to it. It is delivered either as a daily sublingual tablet (Grazax for grass pollen, Acarizax for house dust mite, Itulazax for tree pollen) or as a series of subcutaneous injections at a specialist clinic. The course usually runs for three years.

The second and older meaning is the Kenalog injection. Kenalog is a brand name for triamcinolone, a long-acting steroid that was once given as a single seasonal injection at the start of the pollen season. It treats symptoms by broadly suppressing inflammation across the body. It is no longer offered on the NHS for hay fever and the regulator has restricted advertising of it.

These two approaches share the word “vaccine” only in the loosest sense. Allergen immunotherapy is genuinely disease-modifying – it aims to change how your immune system responds to an allergen in the long term. The Kenalog injection is a high-dose systemic steroid with significant side-effect concerns. The rest of this article focuses on the modern treatment, which is what NHS allergy specialists, NICE and BSACI now recommend for severe hay fever that has not responded to standard treatments.

How NHS allergen immunotherapy actually works

Allergen immunotherapy uses repeated small doses of a specific allergen to retrain the immune system. Rather than simply blocking histamine the way an antihistamine tablet does, it gradually shifts the immune response so the body becomes less reactive to the trigger over time. The modern NHS-approved form is the sublingual tablet, dissolved under the tongue each morning.

Grazax contains a standardised dose of timothy grass pollen extract. Acarizax contains house dust mite extract. Itulazax contains birch and related tree pollen extract. The first tablet is taken in clinic under medical supervision because there is a very small risk of a significant allergic reaction. Patients are observed for around 30 minutes. After that, all further tablets are taken at home.

The tablet course runs for three years. Seasonal pollen tablets such as Grazax and Itulazax are taken for the six months that include and surround the pollen season each year. Year-round allergens such as dust mite are treated with a daily tablet throughout the three years. Symptom benefit typically begins within a few weeks of starting and accumulates over the first season, with progressive improvement during the second and third years. Published trials show that the benefit often persists for several years after completing the full course.

Subcutaneous immunotherapy uses graded injections at a specialist allergy clinic – weekly during the build-up phase and then monthly during maintenance for three years. It is mostly used in the UK for severe bee and wasp venom allergy and occasionally for pollen allergy where tablets are not suitable.

What NICE and BSACI actually recommend

The British Society for Allergy and Clinical Immunology (BSACI) sets the UK clinical standard for hay fever management. Its guideline follows a stepwise approach. Step one is allergen avoidance where practical and oral non-sedating antihistamines such as cetirizine, loratadine or fexofenadine. Step two adds an intranasal corticosteroid spray such as fluticasone or mometasone, used regularly through the season rather than only when symptoms break through. Step three combines these treatments and may consider a leukotriene receptor antagonist or short course of oral steroids for very troublesome breakthrough symptoms. Step four is specialist referral and consideration of allergen immunotherapy.

NICE has issued positive technology appraisal guidance for several sublingual immunotherapy products. Itulazax was recommended for moderate-to-severe tree pollen allergic rhinitis after standard treatments have failed, which means NHS funding is in place for adults across England, Wales and Northern Ireland. Grazax has been available on the NHS for severe grass pollen hay fever in adults and in children from age 5. Acarizax has NHS funding for severe dust mite allergic rhinitis from age 12. Scotland has parallel decisions made by the Scottish Medicines Consortium (SMC).

In all cases, NHS access requires that standard treatments have been properly tried and have failed to control symptoms, that the allergy has been confirmed with skin-prick or specific IgE testing, and that the patient is medically suitable. The result is that allergen immunotherapy is genuinely available on the NHS in 2026. The practical bottleneck is referral capacity and allergy clinic waiting times.

Why Kenalog is not on the NHS for hay fever

Kenalog (triamcinolone acetonide) was once given on the NHS as a single seasonal injection for severe hay fever. The treatment fell out of NHS use many years ago because the risk-benefit balance was not favourable for a generally non-life-threatening seasonal condition. A single dose of triamcinolone delivers a high systemic steroid load that persists in the body for around six to eight weeks. Possible side effects include disturbed sleep, mood changes, raised blood sugar, increased appetite and weight gain, skin thinning, and contributions to long-term bone density loss with repeated annual use.

Kenalog is not licensed in the UK for the treatment of hay fever. It is licensed for some other conditions on prescription, but using it for seasonal allergic rhinitis is an off-label use. In 2026 the MHRA and the Advertising Standards Authority continue to act against private clinics, beauty salons and individual practitioners advertising Kenalog as a “hay fever jab” or “hay fever vaccine” on social media.

Some private clinics in the UK still offer the injection. Patients can legally consent to off-label treatment in a private setting, but they should be aware that they are receiving a treatment that the NHS has discontinued and that the regulator has flagged for advertising concerns. It is not equivalent to immunotherapy in any clinical sense. It suppresses inflammation for a few weeks. It does not retrain the immune system. BSACI guidance specifically advises against the routine use of long-acting depot steroid injections for seasonal allergic rhinitis.

Typical UK costs and waiting times in 2026

On the NHS, allergen immunotherapy is free at the point of access. The main cost to the patient is time. NHS allergy clinic waiting times vary considerably across the UK. Some regions can offer a first specialist appointment within three to four months. Others have waiting times of twelve to eighteen months. Patients in areas served by large allergy centres such as London, Manchester and Cambridge may have shorter waits than those in regions with fewer specialist clinics.

Privately, allergen immunotherapy in a UK clinic typically costs approximately £300 to £400 for the supervised first dose, then around £120 to £150 a month for medication during the active treatment period. The total private cost for a three-year sublingual tablet course comes to roughly £4,000 to £5,500 depending on the clinic and the product. Skin-prick or specific IgE testing in a private clinic ranges from approximately £150 to £300. Subcutaneous immunotherapy is more expensive privately because of the cost of regular supervised injection visits.

Kenalog injections at a private clinic typically cost approximately £80 to £150 per injection. As noted above, the NHS does not offer this for hay fever.

Standard hay fever medication on the NHS is either free with a prescription for those who are exempt or around £10 per prescription item for those who pay. Many antihistamines and steroid nasal sprays are also available over the counter for a few pounds. Eye drops for allergic conjunctivitis are similarly inexpensive. Anyone considering private immunotherapy should ask about supervision arrangements, the qualifications of the prescribing clinician, and what happens if a reaction occurs at the first supervised dose.

How to access NHS immunotherapy – a step-by-step plan

The first step is booking a routine GP appointment. Bring a clear account of your symptoms, what you have already tried, the doses used, and for how long. The criteria for NHS specialist referral are moderate-to-severe symptoms that have not been controlled by a proper trial of regular oral antihistamines combined with an intranasal corticosteroid spray used daily through the pollen season. By “proper trial” the BSACI guideline means daily use of an intranasal steroid spray for at least four to six weeks at the correct dose – not occasional use when symptoms happen to break through. Many patients use nasal steroid sprays sub-optimally and understandably feel they have not worked, when in fact they have not been given a fair trial.

If you have used the spray correctly and your symptoms still affect your sleep, work or daily life, ask your GP for a referral to an NHS allergy clinic for assessment for immunotherapy. The specialist will take a detailed history and arrange skin-prick or specific IgE blood testing to confirm which allergen is responsible. The first supervised tablet dose is then arranged in clinic. Subsequent tablets are taken daily at home for three years. Annual review visits take place during the course.

If you are not already known to have asthma, the GP may arrange spirometry or peak flow testing to check for uncontrolled asthma, which is a contraindication to starting immunotherapy. While you wait for the referral appointment, continue all standard treatments through the pollen season. Saline nasal rinses, wraparound sunglasses to reduce pollen reaching the eyes, and showering after time outdoors can all help with symptom control in the meantime.

Frequently Asked Questions

Is there a hay fever vaccine in the UK in 2026?

There is no single-jab “hay fever vaccine” in the way the phrase suggests. What exists is allergen immunotherapy – daily sublingual tablets such as Grazax, Acarizax or Itulazax taken over three years, or graded allergen injections given at a specialist clinic. The other meaning people attach to the phrase is the Kenalog steroid injection, which is no longer offered on the NHS for hay fever and which the MHRA has restricted in private advertising. The modern NHS pathway for moderate-to-severe hay fever that has not responded to standard treatment is a referral to an allergy clinic for sublingual immunotherapy.

How do I get NHS immunotherapy for hay fever?

Book a routine GP appointment. Describe your symptoms, what you have tried and for how long. If standard treatments – oral antihistamines combined with a daily intranasal corticosteroid spray used regularly through the season – have not controlled your symptoms, ask for a referral to an NHS allergy clinic. The clinic will confirm the allergy with skin-prick or specific IgE blood testing and assess your suitability for sublingual immunotherapy. The first dose is supervised in clinic. Subsequent tablets are taken at home each day for three years, with annual review appointments.

Can I get a Kenalog injection on the NHS for hay fever?

No. The NHS withdrew Kenalog for the treatment of hay fever many years ago because the risks of a long-acting systemic steroid were not justified for a seasonal condition when effective standard treatments and a modern disease-modifying alternative exist. Kenalog is not licensed in the UK for hay fever. BSACI guidance specifically advises against routine long-acting steroid injections for seasonal allergic rhinitis. Some private clinics still offer Kenalog, but the MHRA has acted against advertising of it as a hay fever vaccine on social media.

How much does private hay fever immunotherapy cost in the UK in 2026?

A typical private course costs approximately £300 to £400 for the supervised first dose, then around £120 to £150 a month for medication during the active treatment period. The total three-year private cost for sublingual tablets is roughly £4,000 to £5,500. Skin-prick allergy testing is approximately £150 to £300. Subcutaneous injections at a clinic are more expensive because of regular supervised visits. NHS immunotherapy is free at the point of access, though waiting times for the first specialist appointment can range from a few months to over a year depending on your area.

How long does sublingual immunotherapy take to work?

Some symptom improvement is usually noticed within a few weeks of starting, with more meaningful benefit through the first pollen season. Most published trials show progressive improvement over the three-year course, with the largest benefit in the second and third years. Sustained benefit lasting several years after completing the course is the treatment goal and is supported by long-term follow-up data. This is not an instant fix. It is a commitment to a daily tablet over three years, taken under specialist guidance.

Who is not suitable for allergen immunotherapy?

People with active uncontrolled asthma, certain rare immunological conditions, recent malignancy under active treatment, and severe cardiovascular disease that would make emergency adrenaline use difficult are generally not suitable. Those who cannot reliably commit to a daily tablet for three years may also not be appropriate candidates. Pregnancy is a contraindication to starting immunotherapy but not usually to continuing it under specialist supervision. Age limits apply: Grazax from age 5, Acarizax from age 12, and Itulazax from age 18 in the UK. The specialist allergy clinic confirms suitability during the assessment visit.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.